BACKGROUND: Variability in CD4 T-cell counts has been described for both healthy and HIV-infected persons. It may influence decisions with respect to initiation and monitoring of antiretroviral treatment. OBJECTIVE: to measure the effect of timing of blood sampling for blood cell count measurement. METHOD: The study population consisted of 71 Ethiopian patients in an observational cohort, either being monitored prior to HAART (n = 40) or receiving HAART (n = 31) at an ART Clinic in Addis Ababa. RESULT: The median CD4 count demonstrated significantly increasing trends from the morning (8 am) to the afternoon (4 pm), both for patients on HAART (increase of 137 CD4 cell/microl; p = 0.003) and for patients initiating HAART (increase of 56 CD4 cells/microl; p = 0.038). This trend was also observed for CD8+ and CD3+ T-lymphocytes, (initiating HAART p = 0.002 and p = 0.001; patients on HAART p = 0.015 and p = 0.004, respectively). CONCLUSION: The implications of these findings are for the decision to start HAART or the decision to start prevention of opportunistic infections in Ethiopian patients on HAART.
BACKGROUND: Variability in CD4 T-cell counts has been described for both healthy and HIV-infectedpersons. It may influence decisions with respect to initiation and monitoring of antiretroviral treatment. OBJECTIVE: to measure the effect of timing of blood sampling for blood cell count measurement. METHOD: The study population consisted of 71 Ethiopian patients in an observational cohort, either being monitored prior to HAART (n = 40) or receiving HAART (n = 31) at an ART Clinic in Addis Ababa. RESULT: The median CD4 count demonstrated significantly increasing trends from the morning (8 am) to the afternoon (4 pm), both for patients on HAART (increase of 137 CD4 cell/microl; p = 0.003) and for patients initiating HAART (increase of 56 CD4 cells/microl; p = 0.038). This trend was also observed for CD8+ and CD3+ T-lymphocytes, (initiating HAART p = 0.002 and p = 0.001; patients on HAART p = 0.015 and p = 0.004, respectively). CONCLUSION: The implications of these findings are for the decision to start HAART or the decision to start prevention of opportunistic infections in Ethiopian patients on HAART.
Authors: Alan L Schooley; Pocha Samuel Kamudumuli; Sitaram Vangala; Chi-Hong Tseng; Chifundo Soko; Julie Parent; Khumbo Phiri; Andreas Jahn; Dan Namarika; Risa M Hoffman Journal: Open Forum Infect Dis Date: 2016-08-29 Impact factor: 3.835
Authors: Luuk Gras; Margaret May; Lars Peter Ryder; Adam Trickey; Marie Helleberg; Niels Obel; Rodolphe Thiebaut; Jodie Guest; John Gill; Heidi Crane; Viviane Dias Lima; Antonella dʼArminio Monforte; Timothy R Sterling; Jose Miro; Santiago Moreno; Christoph Stephan; Colette Smith; Janet Tate; Leah Shepherd; Mike Saag; Armin Rieger; Daniel Gillor; Matthias Cavassini; Marta Montero; Suzanne M Ingle; Peter Reiss; Dominique Costagliola; Ferdinand W N M Wit; Jonathan Sterne; Frank de Wolf; Ronald Geskus Journal: J Acquir Immune Defic Syndr Date: 2019-03-01 Impact factor: 3.731
Authors: Luuk Gras; Ronald B Geskus; Suzanne Jurriaans; Margreet Bakker; Ard van Sighem; Daniela Bezemer; Christophe Fraser; Jan M Prins; Ben Berkhout; Frank de Wolf Journal: PLoS One Date: 2013-05-27 Impact factor: 3.240
Authors: Abraham Malaza; Joël Mossong; Till Bärnighausen; Johannes Viljoen; Marie-Louise Newell Journal: PLoS One Date: 2013-07-23 Impact factor: 3.240